Why CONMED (CNMD) Shares Are Falling Today
CONMED (NYSE:CNMD) shares fell about 4.9% after BofA Securities downgraded the stock to Underperform from Neutral, citing growth concerns. BofA cut its 2027 organic growth estimate to 4.5% from 5.8% and 2027 EPS to $4.54 from $4.67 (vs. $4.79 consensus), while keeping a $40 price target. Shares later traded around $34.26.
How this was made
The 30-second read
Why it matters
A downgrade to Underperform with reduced growth/EPS estimates is likely to weigh on CNMD’s relative performance and near-term risk appetite, even with an unchanged $40 price target.
Market read
Traders can use the downgrade and revised 2027 model inputs as a fresh expectation reset for CNMD’s near-term sentiment and positioning.
What to watch
The article doesn’t discuss CONMED-specific fundamentals beyond the analyst model changes; follow-on revisions from other banks and any company commentary could quickly alter the narrative.
Background
BofA cited concerns about CONMED’s future growth and updated its 2027 organic growth and EPS assumptions.
Ticker impact
BofA downgraded CONMED to Underperform and cut its 2027 organic growth and EPS estimates, driving a ~5% intraday drop.
Likely continued underperformance versus peers near-term as investors reprice the lowered 2027 growth/EPS path; any rebound depends on follow-on analyst revisions and broader medical-tech tape.
The article cites a specific downgrade plus concrete model changes (growth to 4.5% from 5.8%, EPS to $4.54 from $4.67) while keeping the $40 price target, which typically pressures near-term positioning even without a target cut.
Market effects
Highlights how medical-device import/tariff uncertainty and analyst growth concerns can pressure the broader med-tech complex.
No specific regional impact beyond US-listed med-tech sentiment.
Tariff/international supply-chain risk framing could matter for globally sourced medical equipment, but the article’s new catalyst is analyst-driven for CNMD.
Counterpoint
The price target was maintained at $40, and the stock partially retraced losses, suggesting some investors may view the downgrade as already priced or less severe than a target cut.
Key entities
- companyCONMED
Medical tech company whose shares fell after BofA downgraded it and lowered 2027 growth/EPS estimates.
- analyst_firmBofA Securities
Issued the downgrade to Underperform and revised its 2027 organic growth and EPS estimates.
